Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 159
- Registration Number
- NCT02336165
- Locations
- 🇦🇺
Research Facility, Melbourne, Australia
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 65
- Registration Number
- NCT02281084
- Locations
- 🇧🇪
Local Institution - 800, Liège, Belgium
🇵🇱Local Institution - 900, Warszawa, Poland
🇪🇸Local Institution - 300, Granada, Spain
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 330
- Registration Number
- NCT01993810
- Locations
- 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 104
- Registration Number
- NCT01975831
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Virginia Division of Hematology and Oncology, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.